位置:成果数据库 > 期刊 > 期刊详情页
复发转移性食管癌患者紫杉醇化疗联合50Gy放疗的预后与安全性
  • ISSN号:1674-8182
  • 期刊名称:《中国临床研究》
  • 时间:0
  • 分类:R735.1[医药卫生—肿瘤;医药卫生—临床医学] R45[医药卫生—治疗学;医药卫生—临床医学]
  • 作者机构:[1]哈励逊国际和平医院肿瘤内科,河北衡水053000, [2]河北医科大学第四医院肿瘤研究所,河北石家庄050011
  • 相关基金:国家自然科学基金(81101854)
中文摘要:

目的分析紫杉醇化疗联合50Gy放疗治疗复发转移性食管癌的临床疗效和安全性。方法回顾性分析2015年1月至12月收治的83例复发转移性食管癌患者的临床资料,按照治疗方法的不同分为紫杉醇化疗联合50Gy放疗组(治疗组,39例)和50Gy放疗组(对照组,44例)。比较两组患者接受治疗后的近期疗效、不良反应发生率,3、6个月生存率。结果治疗组的总有效率明显高于对照组(79.5%vs52.3%,P〈0.05)。治疗组与对照组3个月的生存率分别为100%、95.5%,差异无统计学意义(P〉0.05),6个月的生存率分别为100%、86.4%,差异有统计学意义(P〈0.05)。两组恶心呕吐、食管炎、血小板减少、白细胞减少发生率比较差异无统计学意义(P均〉0.05)。结论采用紫杉醇化疗联合50Gy放疗方案治疗复发转移性食管癌有较好的临床疗效,患者耐受性好,不良反应发生率低,安全性高。

英文摘要:

Objective To study the clinical effect and safety of paclitaxel chemotherapy combined with 50 gy radiotherapy in the treatment of recurrent and metastatic esophageal cancer. Methods A retrospective analysis was performed on the data of 83 patients with recurrent and metastatic esophageal cancer from January 2015 to December 2015. According to treatment method, the patients were divided into paclitaxel chematherapy plus 50 gy radiotherapy group (treatment group, n = 39) and 50 gy radiotherapy group (control group, n = 44). The short term curative effects, the incidence of adverse re- action and the survival rates of 3-,6- month were analyzed and compared between two groups. Results The total effective rate of treatment group was significantly higher than that of control group (79.5% vs 52.3% , P 〈 0.05 ). There was no sig- nificant difference in 3-month survival rate between treatment group and control group ( 100% vs 95.5% , P 〉 0.05 ) , but 6-monthin survival rate in treatment group was significantly higher than that in control group ( 100% vs 86.4% , P 〈 0. 05 ). There were no significant differences in incidences of nausea and vomiting, esophagitis, thrombocytopenia and leuko- penia between two groups ( all P 〉 0.05). Conclusions The combined treatment of paclitaxel chemotherapy and 50 gy ra- diotherapy has better clinical curative effect and the advantages of well tolerance of patients,lower incidence of adverse re- action and higher safety for the treatment of recurrent and metastatic esophageal cancer.

同期刊论文项目
同项目期刊论文
期刊信息
  • 《中国临床研究》
  • 中国科技核心期刊
  • 主管单位:国家卫生和计划生育委员会
  • 主办单位:中华预防医学会
  • 主编:徐肇敏
  • 地址:南京市山西路57号
  • 邮编:210009
  • 邮箱:zglczz@163.com
  • 电话:025-83243580
  • 国际标准刊号:ISSN:1674-8182
  • 国内统一刊号:ISSN:32-1811/R
  • 邮发代号:28-234
  • 获奖情况:
  • 国内外数据库收录:
  • 被引量:10089